TTrialPathMatch Me to Trials
← Back to trials
RecruitingMultiple Myeloma

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Eligible age

18+ yrs

Accepts

All genders

Locations

13 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

You may qualify if…

  • ✓ History of relapsed and/or refractory multiple myeloma (RRMM) treated with at least 3 (Part 1), history of RRMM or at least 1 but not greater than 3 prior anti-myeloma treatment (PAMT) regimens (Part 2, Arms A, B, C, and D); history of quadruple class exposed RRMM having received BCMA TCE as the most recent line of therapy (Part 2, Arm E).
  • ✓ Measurable multiple myeloma (MM) as per International Myeloma Working Group (IMWG).
  • ✓ Eastern Cooperative Oncology Group performance status of 0-1.
  • ✓ Adherence to contraception requirements.

You may not qualify if…

  • ✕ Prior treatment with alnuctamab (Arm A), mezigdomide (Arms B and E), iberdomide (Arm C), elranatamab (Arm D) or BCMA-targeting therapy (Part 2 Arms A and D).
  • ✕ Prior treatment with GPRC5D-targeting therapies as of Protocol Amendment 02 (Part 1 and Part 2).
  • ✕ Other protocol-defined inclusion/exclusion criteria apply.

Where it's recruiting

Alabama

Birmingham

Arizona

Phoenix

Florida

Jacksonville

Georgia

Atlanta

Minnesota

Rochester

New Jersey

Hackensack

New York

Buffalo · New York

Pennsylvania

Pittsburgh

Tennessee

Nashville

Source: ClinicalTrials.gov · NCT06121843 · last updated 2026-07-16